Lower GI
2026-05-18
OPERA Trial (5-year rectal preservation)
OPERA post-hoc: W14 DRE+rectoscopy reliably identifies cCR; 5-yr organ preservation 75% vs 83% (Arm A vs B, p=0.24).
- π Post-hoc analysis of OPERA trial; N=141 with CTRE at W14 (122/141, 87%)
- π W14 assessment: DRE + rectoscopy (Β±MRI); defined CR, near-CR (nCR), partial response (PR)
- π W14 good response (cCR+nCR): 76%; PR: 24%
- π Good response by arm: Arm B 88% vs Arm A 65% (p=0.004)
- π MRI TRG1-2 concordance in W14 CR pts: 98% (80/82)
- π 5-yr organ preservation rates
- By arm: 75% (Arm A) vs 83% (Arm B), p=0.24
- By response depth: cCR 81% vs nCR 77% (similar)
- β οΈ Post-hoc analysis; W14 response classification not prespecified as primary decision gate in original OPERA design
- β οΈ nCR likely reflects radiation side effects (mucosal change), not residual tumor; authors caution against using nCR to justify radical surgery
- π Original OPERA trial compared standard vs contact X-ray boost; this analysis cuts across both arms to validate timing of response assessment
- β Whether W14 CTRE alone (without W24 MRI) is sufficient to safely defer W24 reassessment in nCR pts
π Sources Β· π¦ 1 tweet
Day FOUR of #ESTRO26 Coverage by OncoAlert π¨
— OncoAlert (@OncoAlert) May 18, 2026
Five-year Results of the OPERA Trial: When and How to Assess Tumor Response to Guide Rectal Preservation Presented by Syrine Ben Dhia π«π· #RadOnc β’οΈ
This post-hoc analysis of the OPERA trial evaluated early tumor response⦠pic.twitter.com/KUanFTxeFh